Qualigen Therapeutics (QLGN)
(Delayed Data from NSDQ)
$0.20 USD
-0.01 (-3.19%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $0.19 -0.01 (-3.55%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Qualigen Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 0 | 7 | 18 | 24 | 2 |
Receivables | 0 | 1 | 1 | 1 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 2 | 1 | 1 | 0 |
Other Current Assets | 1 | 2 | 1 | 3 | 1 |
Total Current Assets | 1 | 11 | 21 | 28 | 2 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 6 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 0 | 0 | 0 | 0 |
Total Assets | 2 | 19 | 23 | 29 | 3 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 1 | 1 | 1 | 1 |
Current Portion Long-Term Debt | 1 | 1 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 1 | 2 | 2 | 1 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 5 | 2 | 9 | 0 |
Total Current Liabilities | 4 | 9 | 5 | 10 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 4 | 10 | 6 | 11 | 2 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 2 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 115 | 111 | 101 | 85 | 80 |
Retained Earnings | -117 | -103 | -85 | -67 | -80 |
Other Equity | 0 | 2 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -2 | 9 | 17 | 18 | 1 |
Total Liabilities & Shareholder's Equity | 2 | 19 | 23 | 29 | 3 |
Total Common Equity | -2 | 9 | 17 | 18 | 0 |
Shares Outstanding | 5.10 | 4.20 | 2.90 | 2.30 | 0.00 |
Book Value Per Share | -0.41 | 2.09 | 5.71 | 7.96 | -0.43 |
Fiscal Year End for Qualigen Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | 0 | 2 | 1 |
Receivables | NA | NA | 0 | 0 | 1 |
Notes Receivable | NA | NA | 0 | 0 | 0 |
Inventories | NA | NA | 0 | 0 | 2 |
Other Current Assets | NA | 1 | 1 | 1 | 1 |
Total Current Assets | NA | 1 | 1 | 3 | 5 |
Net Property & Equipment | NA | NA | 0 | 0 | 1 |
Investments & Advances | NA | NA | 0 | 0 | 0 |
Other Non-Current Assets | NA | NA | 0 | 0 | 0 |
Deferred Charges | NA | NA | 0 | 0 | 0 |
Intangibles | NA | NA | 0 | 0 | 6 |
Deposits & Other Assets | NA | NA | 1 | 1 | 0 |
Total Assets | NA | 1 | 2 | 4 | 13 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 2 | 2 | 2 |
Current Portion Long-Term Debt | NA | 1 | 1 | 1 | 2 |
Current Portion Capital Leases | NA | NA | 0 | 0 | 0 |
Accrued Expenses | NA | 1 | 1 | 1 | 2 |
Income Taxes Payable | NA | NA | 0 | 0 | 0 |
Other Current Liabilities | NA | 1 | 0 | 2 | 2 |
Total Current Liabilities | NA | 5 | 4 | 6 | 8 |
Mortgages | NA | NA | 0 | 0 | 0 |
Deferred Taxes/Income | NA | NA | 0 | 0 | 0 |
Convertible Debt | NA | NA | 0 | 0 | 0 |
Long-Term Debt | NA | NA | 0 | 0 | 0 |
Non-Current Capital Leases | NA | NA | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | NA | 0 | 0 | 0 |
Total Liabilities | NA | 5 | 4 | 6 | 10 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 115 | 115 | 113 | 113 |
Retained Earnings | NA | -119 | -117 | -114 | -111 |
Other Equity | NA | NA | 0 | 0 | 1 |
Treasury Stock | NA | NA | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -4 | -2 | -2 | 3 |
Total Liabilities & Shareholder's Equity | NA | 1 | 2 | 4 | 13 |
Total Common Equity | 0 | 99,995 | -2 | -2 | 3 |
Shares Outstanding | 9.60 | 6.50 | 5.10 | 5.00 | 5.00 |
Book Value Per Share | 0.00 | 15,383.92 | -0.41 | -0.33 | 0.66 |